SS
SYRE icon

SBI Securities’s Spyre Therapeutics SYRE Stock Holding History

SBI Securities’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444 Hold
5
– – ﹤0.01% 3074
2026
Q1 		$252 Hold
5
– – ﹤0.01% 3131
2025
Q4 		$164 Sell
5
-118
-96% -$3.08K ﹤0.01% 3271
2025
Q3 		$5.88K Buy
123
+112
+1,018% +$1.83K ﹤0.01% 1978
2025
Q2 		$165 Buy
11
+6
+120% +$89 ﹤0.01% 3376
2025
Q1 		$81 Hold
5
– – ﹤0.01% 3515
2024
Q4 		$116 Buy
+5
New +$147 ﹤0.01% 3414

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SBI Securities's SYRE Position: Q2 2026 in Review

SBI Securities held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 5 shares worth $444. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

SBI Securities first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.88K in Q3 2025. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • SBI Securities held 5 shares of Spyre Therapeutics worth $444 as of Q2 2026.
  • SBI Securities left its Spyre Therapeutics share count unchanged in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3074 holding.
  • SBI Securities first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Spyre Therapeutics position peaked at $5.88K in Q3 2025.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.